Case Studies on Impediments to Exports in Small Transition Economies

This series of enterprise case studies grew out from a 1995-1996 research project at IIASA. It acknowledged the importance of export development for the recovery of the economies of Central and Eastern Europe following their deep transformational recession in 1990-1994. The main goal was a systematic empirical analysis of the different kinds of impediments to exports in various small East European countries. The project included the coordinated elaboration of country studies for seven small transitional economies (Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Romania, Slovakia and Slovenia) and the writing of three topical studies. The authors of the country studies and the author of the topical study on Russia were requested to base their work on 20 enterprise case studies each (eventually the Russian study was based on 10 cases). Before the start of the research a common scheme of the enterprise case studies was discussed and agreed upon with the authors. After completing their work the authors were asked to supplement a short version of their case studies to their main text. Eventually it was decided that, due to the length of the full text, two related publications would be arranged, one book made up of the country studies and topical studies, and another of the enterprise case studies. The book was published by Edward Elgar: Cooper, R. and Gács, J. (Eds.) (1997) Trade Growth in Transition Economies: Export Impediments for Central and Eastern Europe, Edward Elgar, Cheltenham, UK. The second publication is the present series of case studies

Case Studies on Impediments to Exports in Small Transition Economies

This series of enterprise case studies grew out from a 1995-1996 research project at IIASA. It acknowledged the importance of export development for the recovery of the economies of Central and Eastern Europe following their deep transformational recession in 1990-1994. The main goal was a systematic empirical analysis of the different kinds of impediments to exports in various small East European countries. The project included the coordinated elaboration of country studies for seven small transitional economies (Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Romania, Slovakia and Slovenia) and the writing of three topical studies. The authors of the country studies and the author of the topical study on Russia were requested to base their work on 20 enterprise case studies each (eventually the Russian study was based on 10 cases). Before the start of the research a common scheme of the enterprise case studies was discussed and agreed upon with the authors. After completing their work the authors were asked to supplement a short version of their case studies to their main text. Eventually it was decided that, due to the length of the full text, two related publications would be arranged, one book made up of the country studies and topical studies, and another of the enterprise case studies. The book was published by Edward Elgar: Cooper, R. and Gács, J. (Eds.) (1997) Trade Growth in Transition Economies: Export Impediments for Central and Eastern Europe, Edward Elgar, Cheltenham, UK. The second publication is the present series of case studies

The Ku Heterodimer and the Metabolism of Single-Ended DNA Double-Strand Breaks

Single-ended double-strand breaks (DSBs) are a common form of spontaneous DNA break, generated when the replisome encounters a discontinuity in the DNA template. Given their prevalence, understanding the mechanisms governing the fate(s) of single-ended DSBs is important. We describe the influence of the Ku heterodimer and Mre11 nuclease activity on processing of single-ended DSBs. Separation-of-function alleles of yku70 were derived that phenocopy Ku deficiency with respect to single-ended DSBs but remain proficient for NHEJ. The Ku mutants fail to regulate Exo1 activity, and bypass the requirement for Mre11 nuclease activity in the repair ofcamptothecin-induced single-ended DSBs. Ku mutants exhibited reduced affinity for DNA ends, manifest as both reduced end engagement and enhanced probability of diffusing inward on linear DNA. This study reveals an interplay between Ku and Mre11 in the metabolism of single-ended DSBsthat is distinct from repair pathway choice at double-ended DSBs

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk